While the future of Celgene (CELG) looks bright in terms of the company's promising pipeline, its present is facing some serious threats. In this video, Fool health-care analyst David Williamson tells investors how the company's present success is absolutely tied to its two key drugs, Revlimid and Vidaza. David highlights the threats to these drugs both in the form of generics, as well as very fierce competition.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
2 Big Risks Threatening Celgene
NASDAQ: CELG
Celgene

2 big risks every Celgene investor needs to be aware of.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.